Padmanabhan Aruna, Baker Julie A, Zirpoli Gary, Sait Sheila N J, Ford Laurie A, Moysich Kirsten B, Baer Maria R
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Leuk Res. 2008 Dec;32(12):1820-3. doi: 10.1016/j.leukres.2008.03.032. Epub 2008 May 12.
Adjuvant chemotherapy and radiation therapy for breast cancer are associated with therapy-related acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS), but little is known about additional risk factors. Thirty-four patients with AML (n=26)/MDS (n=8) following breast cancer (cases) were compared with 2029 breast cancer patients without AML/MDS (controls). Cases were older at breast cancer diagnosis (mean 60.2 years versus 54.5 years; p=0.01) and more commonly had additional cancers (29% versus 4.9%; p<0.0001) and >or=4 first-degree relatives with any type of cancer (OR: 5.37, CI: 1.44-19.9). Thus risk factors for AML/MDS following breast cancer include older age, other cancers and multiple first-degree relatives with cancer.
乳腺癌的辅助化疗和放疗与治疗相关的急性髓系白血病(AML)/骨髓增生异常综合征(MDS)有关,但对于其他风险因素知之甚少。将34例乳腺癌后发生AML(n = 26)/MDS(n = 8)的患者(病例组)与2029例未发生AML/MDS的乳腺癌患者(对照组)进行比较。病例组在乳腺癌诊断时年龄较大(平均60.2岁对54.5岁;p = 0.01),更常见合并其他癌症(29%对4.9%;p<0.0001)以及≥4名患有任何类型癌症的一级亲属(OR:5.37,CI:1.44 - 19.9)。因此,乳腺癌后发生AML/MDS的风险因素包括年龄较大、其他癌症以及多名患有癌症的一级亲属。